Molecular cross-talk between NF-kB and PI3K/AKT signaling pathway, and therapeutic effects of suppressing NF-kB activity by inhibiting PI3K signaling has been previously reported in human Burkitt’s lymphoma and diffuse large B-cell lymphoma [38, 39]. The gene discussed is PIK3CA; the disease is Burkitt lymphoma.